[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"oubai, MD\u002FPhD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100442374","r-cdop-regimen-in-the-treatment-of-newly-diagnosed-non-hodgkins-lymphoma-with-high-tumor-burden-100442374",false,"NCT05040555","R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden","A Prospective Clinical Study of R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden","Inclusion Criteria:\n\n1. Histologically immunohistochemistry and imaging confirmed diffuse large B-cell lymphoma or follicular lymphoma grade 3B;\n2. Has at least one evaluable or measurable lesion according to Lugano response criteria;\n3. Patients with at least one of the following high tumor burden Involvement of at least 3 nodal sites (each with a diameter greater than 3 cm); nodal or extranodal mass \\> 7cm in its greater diameter; Hepatomegaly and splenomegaly (infiltration confirmed by PET-CT; Spleen: female \\> 15cm, male \\> 16cm); Pleural\u002Fperitoneal effusion; Lactate dehydrogenase (LDH) three times the upper limit of normal; PET-CT TMTV \\>220cm3;\n4. Patients previously untreated;\n5. Patients aged over 18 and under 75 years;\n6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0\\~2;\n7. International Prognostic Index (IPI) score \\> 1, or with extranodal mass diameter ≥7cm;\n8. Life expectancy ≥ 6 months;\n9. Left Ventricular Ejection Fraction (LVEF) ≥ 50%;\n10. Patients must sign informed consent and be willing and able to comply with the requirements of visits, treatment, laboratory tests and other research requirements stipulated in the research schedule.\n\nExclusion Criteria:\n\n1. Pregnant or lactation and patients of childbearing age who do not want to take contraceptive measures;\n2. Abnormal liver function \\[total bilirubin \\> 1.5 times of the upper limit of normal value; Alanine aminotransferase\u002FAspartate aminotransferase (ALT \u002F AST) \\> 2.5 times of upper limit of normal value for patients without liver metastasis ; ALT \u002F AST \\> 5 times of upper limit of normal value for patients with liver metastasis \\], abnormal renal function (serum creatinine \\> 1.5 times of upper limit of normal value) ;\n3. Absolute Neutrophil Count (ANC)\\\u003C1.5×10\\^9\u002FL or Platelet (PLT)\\\u003C 75 × 10\\^9\u002FL;\n4. Hypersensitivity to any study drug or its ingredients;\n5. Patients with significant and uncontrolled cardiovascular disease or history;\n6. Persons with mental disorders\u002Funable to obtain informed consent;\n7. Lymphoma infiltrates the central nervous system;\n8. Previous history of malignant tumor;\n9. HIV infection; HBV infection (HBV-DNA\\> 2000 IU\u002Fml);HCV infection (HCV-RNA\\>200 IU\u002Fml);\n10. The investigator determined not suitable to participate in this study.","ALL","18 Years","75 Years",{"count":20,"type":21},64,"ESTIMATED","INTERVENTIONAL",[24],"NA","A single-center, prospective clinical study to evaluate the efficacy and safety of R-CDOP (Rituximab, Cyclophosphamide, Doxorubicin hydrochloride liposome, Vindesine, Prednisone ) in the treatment of newly diagnosed high tumor burden non-Hodgkin's lymphoma, which has previously shown promising efficacy.",[27,28],"Diffuse Large B Cell Lymphoma","Follicular Lymphoma Grade 3B","RECRUITING","2021-09-15",{"date":32,"type":33},"2021-09-16","ACTUAL",{"date":35,"type":33},"2021-08-30",{"date":37,"type":21},"2028-09-01",{"name":39,"class":40},"oubai, MD\u002FPhD","OTHER",""]